← All trials
NCT04854460
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 28, 2021
- Primary completion
- Feb 25, 2021
- Completion date
- Mar 22, 2021
- First posted
- Apr 22, 2021
- Last posted
- Apr 27, 2021
- Enrollment
- 30
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Genuine Research Center, EgyptLead sponsor
- Genuine Research Center, EgyptStudy director
- EVA pharma, EgyptCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.